Effect of Reslizumab on small airways in asthma - RESSAPEA

INTERVENTION: Patients will recieve reslizuamb (n=21) or placebo (n=11) administered intravenously every 4 weeks for 12 consecutive weeks CONDITION: Asthma, Computed tomography, Airways, Reslizumab ; ; PRIMARY OUTCOME: In this study the change from baseline in regional image (HRCT) based hyperinflation (iVlobes) and in iVaw after 12 weeks treatment with reslizumab compared to changes in the placebo group SECONDARY OUTCOME: iRaw, air trapping, internal lobar airflow distribution, low attenuation or emphysema score, blood vessel density, airway wall thickness. Also correlations between changes in HRCT parameters and SGRQ socire, AQLQ score, FEV1/FVC, FVC, FRC, RV/TLC, FeNO and sputum eosinophils will be assessed. INCLUSION CRITERIA: Patients will be aged 18 ‐ 75 years and have a confirmed diagnosis of severe eosinophilic asthma according to ERS/ATS guidelines. All patients will show persistent blood eosinophilia of >0.4 x 10E9/L despite treatment with high doses of inhaled corticosteroids (>1000 ug/day fluticasone equivalent), or >0.15 x 10E9/L despite chronic oral corticosteroid treatment